Effects of Montelukast sodium combined with Salmeterol in treatment of patients with asthma-chronic obstructive pulmonary disease overlap syndrome
Objective:To observe effects of Montelukast sodium combined with Salmeterol in treatment of patients with asthma-chronic obstructive pulmonary disease overlap syndrome(ACOS).Methods:The clinical data of 78 patients with ACOS admitted to this hospital from January 2020 to June 2023 were retrospectively analyzed.According to different treatment methods,they were divided into study group and control group,39 cases in each.The control group was treated with Salmeterol,while the study group was treated with Montelukast sodium on the basis of that of the control group.The clinical efficacy,the pulmonary function indexes[peak expiratory flow(PEF),forced vital capacity(FVC),residual volume/total lung capacity(RV/TLC),inspiratory volume/total lung capacity(IC/TLC),forced expiratory volume in one second(FEV1)]levels,the inflammatory factors[interferon-γ(INF-γ),interleukin-18(IL-18)]levels,the symptoms[asthma control test(ACT),chronic obstructive pulmonary disease score(CAT)and dyspnea assessment scale(mMRC)]scores before and after the treatment,and the incidence of adverse reactions during the treatment were compared between the two groups.Results:The total effective rate of treatment in the study group was 94.87%(37/39),which was higher than 76.92%(30/39)in the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of PEF,FVC,IC/TLC and FEV1 in the study group were higher than those in the control group,the levels of RV/TLC,INF-γ and IL-18 were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the ACT score of the study group was higher than that of the control group,the CAT and mMRC scores were lower than those of the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Montelukast sodium combined with Salmeterol in the treatment of the ACOS patients can improve the total effective rate of treatment,improve the levels of lung function indexes and the symptom scores,and reduce the levels of inflammatory factors.Moreover,it is superior to single Salmeterol treatment.
万方数据
维普
